The Central Government amended the Drugs Rules, 1945, establishing centralized licensing for stem cell therapies, gene therapies, and xenografts under the CLAA framework. This reform ensures uniform oversight, promotes clinical safety, and targets unproven, exploitative medical practices across India.
Click to View MoreSickle Cell Disease is a genetic blood disorder heavily impacting India's tribal populations. The National Sickle Cell Anaemia Elimination Mission aims to screen 7 crore individuals and eradicate the disease by 2047 through aggressive genetic counseling, hydroxyurea therapy, and emerging CRISPR-Cas9 gene-editing solutions.
Click to View MoreUnion Government launched BIRSA 101, India's first indigenous CRISPR gene therapy targeting Sickle Cell Disease. Developed by CSIR-IGIB and SII, this affordable enFnCas9 technology primarily benefits tribal communities, accelerating the National Sickle Cell Elimination Mission 2047
Click to View MoreAMT-130 gene therapy reduces Huntington’s disease progression by 75% over three years via a single injection silencing the mutant gene. This breakthrough redefines treatment, inspiring hope while raising cost-accessibility challenges under India’s Rare Disease Policy.
Click to View More
© 2026 iasgyan. All right reserved
